Cardiotoxicity is a major concern with anthracycline use. To manage this risk, oncologists may use cardioprotective agents like dexrazoxane. Additionally, patients undergo regular echocardiograms and other heart function tests to monitor for early signs of damage. Dose adjustments and alternative drugs may be considered for patients with pre-existing heart conditions.
